CN101108166A - Quantitative nano aerosol and method of manufacturing the same - Google Patents
Quantitative nano aerosol and method of manufacturing the same Download PDFInfo
- Publication number
- CN101108166A CN101108166A CNA2006100993768A CN200610099376A CN101108166A CN 101108166 A CN101108166 A CN 101108166A CN A2006100993768 A CNA2006100993768 A CN A2006100993768A CN 200610099376 A CN200610099376 A CN 200610099376A CN 101108166 A CN101108166 A CN 101108166A
- Authority
- CN
- China
- Prior art keywords
- nano
- aerosol
- surfactant
- biomolecule
- particle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000443 aerosol Substances 0.000 title claims abstract description 92
- 238000004519 manufacturing process Methods 0.000 title description 3
- 239000003814 drug Substances 0.000 claims abstract description 95
- 239000004094 surface-active agent Substances 0.000 claims abstract description 80
- 238000005516 engineering process Methods 0.000 claims abstract description 73
- 238000001035 drying Methods 0.000 claims abstract description 72
- 239000002245 particle Substances 0.000 claims abstract description 69
- 229940079593 drug Drugs 0.000 claims abstract description 66
- 238000002360 preparation method Methods 0.000 claims abstract description 55
- 239000000126 substance Substances 0.000 claims abstract description 50
- 239000004530 micro-emulsion Substances 0.000 claims abstract description 47
- 210000004072 lung Anatomy 0.000 claims abstract description 25
- 239000007788 liquid Substances 0.000 claims abstract description 18
- 239000002904 solvent Substances 0.000 claims abstract description 15
- 239000000203 mixture Substances 0.000 claims description 65
- 239000002105 nanoparticle Substances 0.000 claims description 57
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 50
- 239000003380 propellant Substances 0.000 claims description 49
- 239000008187 granular material Substances 0.000 claims description 32
- -1 fatty acid cane sugar ester Chemical class 0.000 claims description 29
- 238000001694 spray drying Methods 0.000 claims description 23
- 150000001335 aliphatic alkanes Chemical class 0.000 claims description 21
- 230000000694 effects Effects 0.000 claims description 19
- 239000007921 spray Substances 0.000 claims description 19
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 18
- 239000000194 fatty acid Substances 0.000 claims description 18
- 229930195729 fatty acid Natural products 0.000 claims description 18
- 239000006184 cosolvent Substances 0.000 claims description 17
- 230000005540 biological transmission Effects 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 claims description 14
- NNPPMTNAJDCUHE-UHFFFAOYSA-N isobutane Chemical compound CC(C)C NNPPMTNAJDCUHE-UHFFFAOYSA-N 0.000 claims description 14
- 239000004064 cosurfactant Substances 0.000 claims description 13
- 238000004587 chromatography analysis Methods 0.000 claims description 12
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 12
- 238000000926 separation method Methods 0.000 claims description 12
- 150000004945 aromatic hydrocarbons Chemical class 0.000 claims description 11
- 150000001924 cycloalkanes Chemical class 0.000 claims description 11
- 125000005456 glyceride group Chemical group 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 11
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical group COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 claims description 10
- QWTDNUCVQCZILF-UHFFFAOYSA-N isopentane Chemical compound CCC(C)C QWTDNUCVQCZILF-UHFFFAOYSA-N 0.000 claims description 10
- 238000000151 deposition Methods 0.000 claims description 9
- 238000010521 absorption reaction Methods 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 239000001282 iso-butane Substances 0.000 claims description 7
- 235000013847 iso-butane Nutrition 0.000 claims description 7
- 239000001294 propane Substances 0.000 claims description 7
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims description 6
- 102000011632 Caseins Human genes 0.000 claims description 6
- 108010076119 Caseins Proteins 0.000 claims description 6
- 102000002322 Egg Proteins Human genes 0.000 claims description 6
- 108010000912 Egg Proteins Proteins 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- 108010010803 Gelatin Proteins 0.000 claims description 6
- 229930006000 Sucrose Natural products 0.000 claims description 6
- 239000000783 alginic acid Substances 0.000 claims description 6
- 235000010443 alginic acid Nutrition 0.000 claims description 6
- 229920000615 alginic acid Polymers 0.000 claims description 6
- 229960001126 alginic acid Drugs 0.000 claims description 6
- 150000004781 alginic acids Chemical class 0.000 claims description 6
- 239000003945 anionic surfactant Substances 0.000 claims description 6
- 239000003093 cationic surfactant Substances 0.000 claims description 6
- 235000013345 egg yolk Nutrition 0.000 claims description 6
- 210000002969 egg yolk Anatomy 0.000 claims description 6
- 229920000159 gelatin Polymers 0.000 claims description 6
- 239000008273 gelatin Substances 0.000 claims description 6
- 229940014259 gelatin Drugs 0.000 claims description 6
- 235000019322 gelatine Nutrition 0.000 claims description 6
- 235000011852 gelatine desserts Nutrition 0.000 claims description 6
- 229920001282 polysaccharide Polymers 0.000 claims description 6
- 239000005017 polysaccharide Substances 0.000 claims description 6
- 150000004804 polysaccharides Chemical class 0.000 claims description 6
- IJDNQMDRQITEOD-UHFFFAOYSA-N sec-butylidene Natural products CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 claims description 6
- 229940080237 sodium caseinate Drugs 0.000 claims description 6
- 239000008347 soybean phospholipid Substances 0.000 claims description 6
- 229960004793 sucrose Drugs 0.000 claims description 6
- 239000002888 zwitterionic surfactant Substances 0.000 claims description 6
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 claims description 5
- NPNPZTNLOVBDOC-UHFFFAOYSA-N 1,1-difluoroethane Chemical compound CC(F)F NPNPZTNLOVBDOC-UHFFFAOYSA-N 0.000 claims description 5
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 claims description 5
- ATEBGNALLCMSGS-UHFFFAOYSA-N 2-chloro-1,1-difluoroethane Chemical compound FC(F)CCl ATEBGNALLCMSGS-UHFFFAOYSA-N 0.000 claims description 5
- 239000004338 Dichlorodifluoromethane Substances 0.000 claims description 5
- 125000003963 dichloro group Chemical group Cl* 0.000 claims description 5
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 claims description 5
- 235000019404 dichlorodifluoromethane Nutrition 0.000 claims description 5
- 229940087091 dichlorotetrafluoroethane Drugs 0.000 claims description 5
- AFABGHUZZDYHJO-UHFFFAOYSA-N dimethyl butane Natural products CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 claims description 5
- UHCBBWUQDAVSMS-UHFFFAOYSA-N fluoroethane Chemical compound CCF UHCBBWUQDAVSMS-UHFFFAOYSA-N 0.000 claims description 5
- UKACHOXRXFQJFN-UHFFFAOYSA-N heptafluoropropane Chemical compound FC(F)C(F)(F)C(F)(F)F UKACHOXRXFQJFN-UHFFFAOYSA-N 0.000 claims description 5
- 102000039446 nucleic acids Human genes 0.000 claims description 5
- 108020004707 nucleic acids Proteins 0.000 claims description 5
- 150000007523 nucleic acids Chemical class 0.000 claims description 5
- 229920001184 polypeptide Polymers 0.000 claims description 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 5
- 102000004169 proteins and genes Human genes 0.000 claims description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 5
- 239000012798 spherical particle Substances 0.000 claims description 5
- 238000000502 dialysis Methods 0.000 claims description 4
- 238000001764 infiltration Methods 0.000 claims description 4
- 230000008595 infiltration Effects 0.000 claims description 4
- 238000005342 ion exchange Methods 0.000 claims description 4
- 238000001471 micro-filtration Methods 0.000 claims description 4
- 238000001728 nano-filtration Methods 0.000 claims description 4
- 238000000108 ultra-filtration Methods 0.000 claims description 4
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 claims description 3
- 150000001735 carboxylic acids Chemical class 0.000 claims 1
- 239000012530 fluid Substances 0.000 abstract description 12
- 238000012546 transfer Methods 0.000 abstract description 7
- 230000009471 action Effects 0.000 abstract description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 33
- 239000003921 oil Substances 0.000 description 20
- 239000000243 solution Substances 0.000 description 17
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 15
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 12
- 230000002685 pulmonary effect Effects 0.000 description 12
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 11
- 235000010445 lecithin Nutrition 0.000 description 11
- 239000000787 lecithin Substances 0.000 description 11
- 229940067606 lecithin Drugs 0.000 description 11
- 239000011859 microparticle Substances 0.000 description 11
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 9
- 229960002052 salbutamol Drugs 0.000 description 9
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 238000007789 sealing Methods 0.000 description 8
- NHTMVDHEPJAVLT-UHFFFAOYSA-N Isooctane Chemical compound CC(C)CC(C)(C)C NHTMVDHEPJAVLT-UHFFFAOYSA-N 0.000 description 7
- 102000004877 Insulin Human genes 0.000 description 6
- 108090001061 Insulin Proteins 0.000 description 6
- 125000001309 chloro group Chemical group Cl* 0.000 description 6
- 229940125396 insulin Drugs 0.000 description 6
- YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 description 5
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 5
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 229960003237 betaine Drugs 0.000 description 5
- 238000012377 drug delivery Methods 0.000 description 5
- 229960004207 fentanyl citrate Drugs 0.000 description 5
- IVLVTNPOHDFFCJ-UHFFFAOYSA-N fentanyl citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 IVLVTNPOHDFFCJ-UHFFFAOYSA-N 0.000 description 5
- 229920000151 polyglycol Polymers 0.000 description 5
- 239000010695 polyglycol Substances 0.000 description 5
- 238000010561 standard procedure Methods 0.000 description 5
- 238000005303 weighing Methods 0.000 description 5
- 238000013019 agitation Methods 0.000 description 4
- 230000008021 deposition Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 229960001361 ipratropium bromide Drugs 0.000 description 4
- KEWHKYJURDBRMN-ZEODDXGYSA-M ipratropium bromide hydrate Chemical compound O.[Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 KEWHKYJURDBRMN-ZEODDXGYSA-M 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 2
- 206010011732 Cyst Diseases 0.000 description 2
- 201000003883 Cystic fibrosis Diseases 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 238000001856 aerosol method Methods 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 208000031513 cyst Diseases 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 239000002086 nanomaterial Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 206010042953 Systemic sclerosis Diseases 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 238000005100 correlation spectroscopy Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000010297 mechanical methods and process Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000010587 phase diagram Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 238000000935 solvent evaporation Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229940070384 ventolin Drugs 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Images
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention relates to a nanometer grain and rationed nanometer aerosol utilizing the nanometer grain and their preparation method. With comprehensive microemulsion technology and fast drying technology, prepare a plurality of chemical drugs and biologic particles into nanometer grain, so as to enhance the transfer efficiency via lung intake. To be specific, evenly distribute the liquid for dissolving the drug in another non-mixing solvent under the action of surfactant with microemulsion technology. Then, evaporate all the liquid with fast drying technology to get the nanometer grain of drug. The nanometer grain of drug can evenly disperse in a fluid with propellent, so as to get the nanometer preparation of aerosol. The nanometer preparation has stable transfer capacity for the lung intake of drug and can be applied to drugs with lung transfer, oral transfer or nostril transfer.
Description
Technical field
The present invention relates to a kind of nano-particle and utilize the quantitative nano aerosol of this nano-particle and their preparation method.Specifically, the present invention relates to nano-particle, chemicals and the biomolecule of a kind of chemicals and biomolecule quantitative nano aerosol, and preparation method thereof, utilize this method numerous chemicalses and biomolecule can be prepared into nano-particle and can utilize it to be prepared into nano aerosol.
Background technology
Traditionally, utilize lung to suck and realize that the transmission of medicine mainly is to be used for treating the locality disease, as asthma, chronic obstructive pulmonary disease, cyst cystic fibrosis, pneumonia etc.In the last few years, the lung suction developed into a kind of new drug delivery mode and came the therapy system disease, as diabetes, migraine, osteoporosis, acrosclerosis, even anesthesia or the like.In inhalable formulations, deposition and its aerodynamic force particle diameter of drug particles in respiratory system is closely related.It is generally acknowledged to have only particle diameter could effectively be sucked pulmonary less than the granule of 5 μ m, wherein the granule less than 2 μ m can be deposited on bronchus end and alveolar.So, adopt suitable method to prepare tiny drug particles to realize that its efficient transfer at lower respiratory tract and alveolar is vital.
At present, metered dose inhalation aerosol is the main dosage form that lung sucks preparation.The drug particles that is used for metered dose inhalation aerosol traditionally is generally by the Mechanical Method preparation, and its drug particles particle diameter is (particle diameter is generally micron order) greatly, lack of homogeneity, but also bond bad dispersibility easily.These drug particles are difficult to disperse to form the aerosol of stable homogeneous in propellant, their transmission efficiencies in pulmonary after sucking are low.
Summary of the invention
At the existing quantitatively micron existing drug particles bad dispersibility of inhalation aerosol and low this problem of lung transmission efficiency, the invention provides the nano-particle of a kind of chemicals and biomolecule, utilize the quantitative nano aerosol of this preparation of nanoparticles and their preparation method.
One of purpose of the present invention provides the nano-particle of a kind of chemicals or biomolecule.
Another object of the present invention provides the quantitative nano aerosol of a kind of chemicals or biomolecule, and the chemicals in this aerosol or the nano-particle of biomolecule can disperse in propellant uniformly and stably, and in pulmonary high transmission efficiency are arranged.
Another object of the present invention provides the manufacture method of the nano-particle of a kind of chemicals and biomolecule, and this method can obtain the nano-particle of chemicals and biomolecule in conjunction with micro-emulsion technology and quick drying technology.
Another object of the present invention provides the preparation method of the quantitative nano aerosol of a kind of chemicals or biomolecule, this method adds propellant again and can obtain quantitative nano aerosol or directly this nanoparticulate dispersed be obtained quantitative nano aerosol in propellant by being dissolved in the cosolvent in conjunction with the chemicals and the biomolecule nano-particle of microemulsified and quick drying technology acquisition.
Goal of the invention of the present invention is realized by the following technical programs:
The nano-particle of chemicals of the present invention or biomolecule is prepared through microemulsified and quick drying technology combination, and this nano-particle stable state equably is dispersed in the mixture of propellant or propellant and cosolvent.
The even particle size of the nano-particle of this chemicals or biomolecule, particle diameter (particle diameter) is less than 300nm, preferably less than 100nm; Its mean diameter is 1-90nm, preferred 5-50nm.
Wherein, described chemicals and biomolecule comprise various chemicalses, protein, polypeptide, nucleic acid or various active composition and the mixture of depositing or contain the mixture of active component.
Described nano-particle is spherical particle and/or other particle shape;
Described quick drying technology can be spray drying, supersonic jet spray drying, vacuum microwave rapid draing, quick drying tunnel, expansion drying, other quick drying technology or their combination drying technology.
Described microemulsified can be the microemulsion technology of preparing of any routine, with the liquid (water or oil phase) of soluble chemistry medicine or biomolecule at surfactant or contain under the effect of surfactant solution of cosurfactant to be dispersed in and carry out the microemulsion preparation in another immiscible solvent (oil phase or water) with drop form less than 100nm.
Described surfactant comprises anion surfactant such as carboxylic acid type, cationic surfactant such as quaternary, non-ionic surface active agent such as polyglycols type and zwitterionic surfactant such as betaine type or their mixture.
Specifically, described surfactant can be fatty glyceride such as single glyceride, fatty acid cane sugar ester, fatty acid sorbitan ester, fatty acid propylene glycol ester, soybean phospholipid, Radix Acaciae senegalis, alginic acid, sodium caseinate, gelatin and egg yolk etc., other surfactant types also comprises and contains the amino acids ester surfactant, in conjunction with polysaccharide or proteinic high molecular surfactant and granule surface activity agent etc. or their mixture.
Described cosurfactant is generally alcohol, alcohol ether or the carboxylic acid of medium carbochain C3-C8.
Described immiscible solvent can be the alkane of medium carbochain C5-C8, aromatic hydrocarbons, cycloalkane during as oil phase.
The preparation method of the nano-particle of chemicals of the present invention or biomolecule, comprise microemulsified and rapid draing step, wherein microemulsified can be the microemulsion technology of preparing of any routine, and with the liquid (water or oil phase) of soluble chemistry medicine or biomolecule at surfactant or contain under the effect of surfactant solution of cosurfactant to be dispersed in and carry out the microemulsion preparation in another immiscible solvent (oil phase or water) with drop form less than 100nm.
Wherein, the even particle size of the nano-particle of described chemicals or biomolecule, particle diameter (particle diameter) is less than 300nm, preferably less than 100nm; Its mean diameter is 1-90nm, preferred 5-50nm.
Described chemicals and biomolecule comprise various chemicalses, protein, polypeptide, nucleic acid or various active composition and the mixture of depositing or contain the mixture of active component.
Described nano-particle is spherical particle and/or other particle shape.
Described quick drying technology can be spray drying, supersonic jet spray drying, vacuum microwave rapid draing, quick drying tunnel, expansion drying, other quick drying technology or their combination drying technology.
Described surfactant comprises anion surfactant such as carboxylic acid type, cationic surfactant such as quaternary, non-ionic surface active agent such as polyglycols type and zwitterionic surfactant such as betaine type or their mixture.
Specifically, described surfactant can be fatty glyceride such as single glyceride, fatty acid cane sugar ester, fatty acid sorbitan ester, fatty acid propylene glycol ester, soybean phospholipid, Radix Acaciae senegalis, alginic acid, sodium caseinate, gelatin and egg yolk etc., other surfactant types also comprises and contains the amino acids ester surfactant, in conjunction with polysaccharide or proteinic high molecular surfactant and granule surface activity agent etc. or their mixture.
Described cosurfactant is generally alcohol, alcohol ether or the carboxylic acid of medium carbochain C3-C8.
Described immiscible solvent can be the alkane of medium carbochain C5-C8, aromatic hydrocarbons, cycloalkane during as oil phase.
The quantitative nano aerosol of chemicals of the present invention or biomolecule, this aerosol by will through microemulsified and quick drying technology in conjunction with the nanoparticulate dispersed of chemicals that is prepared or biomolecule in propellant or be dispersed in the mixture of cosolvent and propellant and make.
The even particle size of the nano-particle of described chemicals or biomolecule, particle diameter (particle diameter) is less than 300nm, preferably less than 100nm; Its mean diameter is 1-90nm, preferred 5-50nm.
Described chemicals and biomolecule comprise various chemicalses, protein, polypeptide, nucleic acid or various active composition and the mixture of depositing or contain the mixture of active component.
Described nano-particle is spherical particle and/or other particle shape.
Wherein, the amount of chemicals in the every spray of described aerosol or biomolecule is selected according to its corresponding treatment requirement and medicament categories.For example, the amount of chemicals that contains in every spray or biomolecule is 0.01mg-2mg.
Described quick drying technology can be spray drying, supersonic jet spray drying, vacuum microwave rapid draing, quick drying tunnel, expansion drying, other quick drying technology or their Aassociation drying.
Described microemulsified can be the microemulsion technology of preparing of any routine, with the liquid (water or oil phase) of soluble chemistry medicine or biomolecule at surfactant or contain under the effect of surfactant solution of cosurfactant to be dispersed in and carry out the microemulsion preparation in another immiscible solvent (oil phase or water) with drop form less than 100nm.
Described surfactant comprises anion surfactant such as carboxylic acid type, cationic surfactant such as quaternary, non-ionic surface active agent such as polyglycols type and zwitterionic surfactant such as betaine type or their mixture.
Specifically, described surfactant can be fatty glyceride such as single glyceride, fatty acid cane sugar ester, fatty acid sorbitan ester, fatty acid propylene glycol ester, soybean phospholipid, Radix Acaciae senegalis, alginic acid, sodium caseinate, gelatin and egg yolk etc., other surfactant types also comprises and contains the amino acids ester surfactant, in conjunction with polysaccharide or proteinic high molecular surfactant and granule surface activity agent etc. or their mixture.
Described immiscible solvent can be the alkane of medium carbochain C5-C8, aromatic hydrocarbons, cycloalkane during as oil phase.
Described propellant is can produce enough vapour pressures and produce ether, alkane, fluorohydrocarbon, chlorohydrocarbon, chloro fluorohydrocarbon of impelling effect and composition thereof.Preferred propellant is insoluble for the Nano medication granule.Suitable propellant comprises ether, as dimethyl ether; Alkane such as propane, normal butane, iso-butane, isopentane; Fluoric ether, as Difluoroethane (HFC152a), tetrafluoroethane (HFC134a), heptafluoro-propane (HFC227); The chloro fluoric ether, as isceon (CFC11), dichlorodifluoromethane (CFC12), dichlorotetra-fluoroethane (CFC114), dichloro one fluoroethane (HCFC141b), chlorodifluoroethane (HCFC142b), or their mixture propellant.
Described cosolvent can be alkane, aromatic hydrocarbons or the cycloalkane of medium chain C5-C8.
The quantitative nano aerosol of described chemicals or biomolecule can be used as the application that lung transmission, mouth or nose transmit medicine.
The preparation method of the quantitative nano aerosol of chemicals of the present invention or biomolecule, comprise the nano-particle of the chemicals that will obtain after microemulsified and the rapid draing or biomolecule or nano-particle and surfactant mixtures be dispersed in the propellant or be dispersed in cosolvent and the mixture of propellant in step.
In this preparation method, can also comprise a separating step after a microemulsified and the rapid draing, so that the nano-particle of chemicals or biomolecule separates with surfactant.
Described separating step can adopt absorption, ion exchange, chromatography, membrance separation, infiltration, nanofiltration, ultrafiltration, microfiltration, dialysis, separation method such as centrifugal, or their combination separation method.
The even particle size of the nano-particle of described chemicals or biomolecule, particle diameter (particle diameter) are 1-90nm less than its mean diameter of 100nm preferably less than 300nm, preferred 5-50nm.
Described chemicals and biomolecule comprise various chemicalses, protein, polypeptide, nucleic acid or various active composition and the mixture of depositing or contain the mixture of active component.
Described nano-particle is spherical particle and/or other particle shape.
Described quick drying technology can be spray drying, supersonic jet spray drying, vacuum microwave rapid draing, quick drying tunnel, expansion drying, other quick drying technology or their combination drying technology.
Described microemulsified can be the microemulsion technology of preparing of any routine, with the liquid (water or oil phase) of soluble chemistry medicine or biomolecule at surfactant or contain under the effect of surfactant solution of cosurfactant to be dispersed in and carry out the microemulsion preparation in another immiscible solvent (oil phase or water) with drop form less than 100nm.
Described surfactant comprises anion surfactant such as carboxylic acid type, cationic surfactant such as quaternary, non-ionic surface active agent such as polyglycols type and zwitterionic surfactant such as betaine type or their mixture.
Specifically, described surfactant can be fatty glyceride such as single glyceride, fatty acid cane sugar ester, fatty acid sorbitan ester, fatty acid propylene glycol ester, soybean phospholipid, Radix Acaciae senegalis, alginic acid, sodium caseinate, gelatin and egg yolk etc., other surfactant types also comprises and contains the amino acids ester surfactant, in conjunction with polysaccharide or proteinic high molecular surfactant and granule surface activity agent etc. or their mixture.
Described immiscible solvent can be the alkane of medium carbochain C5-C8, aromatic hydrocarbons, cycloalkane during as oil phase.
Described propellant is can produce enough vapour pressures and produce ether, Hydrocarbon, fluoric ether, chloro fluoric ether of impelling effect and composition thereof.Preferred propellant is insoluble for the Nano medication granule.Suitable propellant comprises ether, as dimethyl ether; Alkane such as propane, normal butane, iso-butane, isopentane; Fluoric ether, as Difluoroethane (HFC152a), tetrafluoroethane (HFC134a), heptafluoro-propane (HFC227); The chloro fluoric ether, as isceon (CFC11), dichlorodifluoromethane (CFC12), dichlorotetra-fluoroethane (CFC114), dichloro one fluoroethane (HCFC141b), chlorodifluoroethane (HCFC142b), or their mixture propellant.
Described cosolvent can be alkane, aromatic hydrocarbons or the cycloalkane of medium chain C5-C8.
The present invention combines with quick drying technology by the micro-emulsion technology of routine, successfully develop a kind of preparation method and come the nano-particle of manufacturing chemistry medicine or biomolecule, can disperse uniformly and stably in propellant thereby develop a kind of Nano medication granule, and the quantitative nano aerosol of high transmission efficiency is arranged in pulmonary.Simultaneously, this integrated technology also provides a platform, and it can make nanoparticle with numerous chemicalses and biomolecule, thereby the sucked nanometer formulation that obtains them is realized intravital transmission and treated the disease of locality and general.
Description of drawings
Fig. 1 isobutyltrimethylmethane .-surfactant-albuterol aqueous solution ternary phase diagrams.
Wherein: (surfactant) to the oblique line on base is the biphase isochor of profit from the top among the figure; The figure middle polyline is the microemulsion boundary line; Point is the microemulsion system of being tested.
The particulate transmission electron microscope picture of Fig. 2 Nano medication (the example yardstick is 100nm among the figure).
The particulate particle size distribution of Fig. 3 Nano medication.
Fig. 4 nano-drug preparation (A: when just preparing; B: after four months).
The pulmonary deposition comparison diagram that Fig. 5 Nano medication aerosol is peaceful with breathing heavily pleasure.
The specific embodiment
Microemulsified, promptly preparation of microemulsion is a known technology.Microemulsion is thermodynamically stable, isotropism, appearance transparent or the translucent dispersion that is formed under Action of Surfactant by two kinds of immiscible liquid, wherein a kind of liquid is continuous phase, and another liquid is scattered in wherein with the drop of particle diameter less than 100nm.One of them of two kinds of immiscible liquid is called water (W), and another is oil phase (O) mutually.Common microemulsion is two types of Water-In-Oil (W/O) and oil-in-waters (O/W).
Microemulsion system generally is made up of organic solvent, aqueous solution, surfactant and cosurfactant.Organic solvent commonly used mostly is medium carbochain such as C5～C8 alkane, aromatic hydrocarbons or cycloalkane; Usually have hydrophilic group (hydroxyl etc.) and lipophilic group (alkyl) in the surfactant molecule, easily on the interface of water and oil phase, form adsorption layer, form microemulsion thereby immiscible one in biphase is dispersed in another continuous phase mutually.Surfactant generally comprises anion surfactant such as carboxylic acid type, cationic surfactant such as quaternary, non-ionic surface active agent such as polyglycols type and zwitterionic surfactant such as betaine type or their mixture.Cosurfactant is generally the fatty alcohol and carboxylic acid of medium carbochain C3～C8.Because the particularity of medicine industry, surfactant must be to the people nontoxic or low toxicity and can being absorbed by the body and metabolism, surfactant commonly used with good biocompatibility has fatty glyceride (being mainly single glyceride), fatty acid cane sugar ester, fatty acid sorbitan ester, fatty acid propylene glycol ester, soybean phospholipid, Radix Acaciae senegalis, alginic acid, sodium caseinate, gelatin and egg yolk etc., also comprising of other contains the amino acids ester, in conjunction with polysaccharide/proteinic high molecular surfactant and granule surface activity agent etc. or their mixture.
Utilize microemulsion system to prepare the important research direction that nano material is nanotechnology.In microemulsion system, the nano-liquid droplet of decentralized photo provides the place of a nanoscale in fact, can carry out chemical reaction here, can carry out processing modifiedly to material, can also be based on this comprehensive other technology preparation have the new form and the nano material of performance.The microemulsion system that the present invention promptly makes up based on the surfactant by good biocompatibility is aided with special dry technology and prepares the nano-particle of medicine to improve their lung suction transmission efficiency.
Dry technology of the present invention is a quick drying technology.Because the biphase volatility difference of profit in the microemulsion system adopts general evaporation technology microemulsion system to be damaged because of the two-phase solvent evaporation rate differs.Quick drying technology then can before microemulsion system might change, steam all solvents in the extremely short time simultaneously fast, thereby obtains nano-particle.Quick drying technology commonly used has spray drying technology, supersonic jet spray drying technology, vacuum microwave quick drying technology, quick drying tunnel technology, expansion drying, other quick drying technology or their combination drying technology.
Comprehensive micro-emulsion technology of the present invention and quick drying technology have been formulated a platform.Under this platform technology, numerous chemicalses and biomolecule can be prepared into nano-particle, improve the transmission efficiency that they suck through lung.Specifically, under the effect of surfactant, be dispersed in another immiscible solvent by the liquid of micro-emulsion technology dissolved substance.The liquid that contains medicine is discontinuous phase, and it is scattered in the middle of the immiscible solvent with the drop form less than 100nm.Adopt special dry technology evaporation to remove all liquid then, promptly obtain the nano-particle of medicine.The medicament nano granule can be dispersed in the middle of the fluid that contains propellant, thereby makes the nanometer dosage form of metered dose inhalation aerosol.This nanometer inhalable formulations has highly stable medicine efficiently pulmonary transmission capacity.
The present invention also may adopt isolation technics, and nano-particle is separated with surfactant.Possible isolation technics comprises absorption, ion exchange, chromatography, membrance separation, infiltration, nanofiltration, ultrafiltration, microfiltration, dialysis, separation method such as centrifugal, or their combination separation method.
With respect to tablet and injection, utilizing lung suction preparation to carry out drug delivery is an emerging technology.Lung sucks preparation and is mainly used to treat pulmonary disease such as asthma, chronic obstructive pulmonary disease, cyst cystic fibrosis, pneumonia etc. traditionally.Because pulmonary's absorption area is big, rich blood vessel is easy to drug absorption.People recognize the effective ways of still treating systemic disease through the lung drug delivery, it have no gastrointestinal tract Degradation, no liver first-pass effect, drug absorption rapidly, directly enter advantages such as body circulation, good patient compliance, dosage reduce, toxic and side effects is little after the drug absorption.Metered dose inhalation aerosol is present the most frequently used inhalable formulations.Wherein propellant is those ether, Hydrocarbon, fluoric ether, chloro fluoric ether or its mixture that can produce enough vapour pressures and produce the impelling effect.Preferred propellant is insoluble for the Nano medication granule.Suitable propellant comprises ether, as dimethyl ether; Alkane such as propane, normal butane, iso-butane, isopentane; Fluoric ether, as Difluoroethane (HFC152a), tetrafluoroethane (HFC134a), heptafluoro-propane (HFC227); The chloro fluoric ether, as isceon (CFC11), dichlorodifluoromethane (CFC12), dichlorotetra-fluoroethane (CFC114), dichloro one fluoroethane (HCFC141b), chlorodifluoroethane (HCFC142b), or their mixture propellant.This metered dose inhalation aerosol also may contain a spot of cosolvent, and cosolvent can be alkane, aromatic hydrocarbons or the cycloalkane of medium chain C5-C8.
Be surfactant below with lecithin, with the isopropyl alcohol is that cosurfactant is the preparation method that example illustrates microemulsified and rapid draing technology and aerosol, at this only as example, be not difficult to find out, any chemicals can adopt identical preparation technology and method to carry out the preparation of nanoparticles and the aerosol preparation of chemicals and biomolecule with biomolecule, wherein, the surfactant of employing, cosurfactant, water, oil phase etc. can adopt respective substance known in the art to replace and can not change invention effect of the present invention.
The structure of microemulsion system
Lecithin is dissolved in isopropyl alcohol and makes surfactant solution (its mass ratio is a lecithin: isopropyl alcohol=1: 3), oil phase is an isobutyltrimethylmethane., and water is 15% (mass percent concentration) albuterol aqueous solution.Surfactant solution and oil phase isobutyltrimethylmethane. are mixed with a series of mixed liquor, and both mass ratioes were from 5: 95 to 95: 5 in the mixed liquor, and the mass percent of surfactant solution in mixed liquor risen progressively with 5%.Then the albuterol aqueous solution is dripped in mixed liquor, and vibration, up to its muddiness, and calculating water, oil phase and surfactant phase three's mass ratio is drawn on and promptly gets its phasor among the DeltaGraph, as shown in Figure 1.In scope shown in the phasor, all can form water-in-oil microemulsion.
The drying of microemulsion
The drying of microemulsion can be selected spray drying for use, only needs single stepping can obtain the nano-particle of medicine fast.Obviously, according to spirit of the present invention, the drying of microemulsion can adopt any quickly drying method, for example can be supersonic jet spray drying technology, vacuum microwave quick drying technology, quick drying tunnel technology, expansion drying, other quick drying technology or their combination drying technology.At this is the drying of Nanometer Particles technology that example illustrates chemicals or biomolecule with the spray drying only, and other dry technology is enumerated no longer one by one, but can know those skilled in the art with other the exploitativeness of dry technology.
The particulate Standard Operating Procedure of preparation Nano medication is summarized as follows.During spray drying, the standard operation state of spray dryer is 120 ℃ for the gas access temperature, and the Compressed Gas flow velocity is 580L/ hour, and outlet temperature transfers to temperature and be stabilized in 80 ℃ by the flow velocity of regulating pump.Keep this jet velocity, microemulsion is carried out spray drying.Finish, use cosolvent, reclaim the dry thing that is deposited in spray chamber, whirlwind centrifuge and the catcher as low alkane (normal heptane) dissolving.Natural drying under the room temperature is removed cosolvent, as low alkane (normal heptane), obtains nanometer albuterol granule and surfactant mixtures.
Show that through transmission electron microscope observing the Nano medication particle grain size that is generated by the microemulsion drying is obviously less than 100nm, mean diameter is between 5-50nm, and the granular size homogeneous is spherical more, also can comprise differential mode granule (Fig. 2).Measure nano particle diameter with the photon correlation spectrometry and distribute, its granule mean diameter is 18nm (Fig. 3).
The preparation of aerosol
According to the requirement of conventional therapy and the kind of medicine, the chemicals that contains in general every jet stream cloud agent or the amount of biomolecule are 0.01mg-2mg, and for example the each dosage of albuterol is 100～200 μ g.Get certain amount of nano drug particles and surfactant mixtures, place aerosol container.Add a spot of low alkane such as normal heptane dissolving surfactant and dispersing nanometer drug particles, use quantitative valve (100 μ l) sealing then.Then inject fluoric ether HFC134a, can make and all disperse and extremely stable supernatant liquid (Fig. 4 A).Place after four months, deposit-free produces, and does not also have floating thing and (Fig. 4 B) occur.So utilize the Nano medication granule can successfully prepare highly stable aerosol, good dispersity has shown that they have excellent ability in the pulmonary drug transmission.
The test that pulmonary drug is transmitted
Aerosol to preparation has carried out pulmonary drug transmission test respectively, and the pulmonary drug transmission test of aerosol is to adopt lung model-carry out under the gas flow rate 28.3L/min of standard.This is the detection method of a standard, and quilt many countries in the world closes in its pharmacopeia.Be deposited on second rank and following granule, its aerodynamics diameter is referred to as and can sucks granule less than 5.8.Tested the pulmonary deposition of nanometer formulation in this research, and breathed heavily happy peaceful (Ventolin) work one relatively (Fig. 5) with suction micron preparation commonly used.
By testing result, the nanometer medicament the deposition of bottleneck throat be starkly lower than commercially available medicine breathe heavily happy peaceful, show the atomizing of nanometer formulation after bulky grain few, the good flowing properties of particle.After entering branch stepwise particle diameter sampler, Nano medication mostly is deposited on Lower Half, the 6th rank especially, the 7th rank and filter course, be higher than far away breathe heavily happy rather in the drug delivery amount of this position, and this some exactly corresponding the alveolar in the human body.So the nanometer medicament can improve targeting (alveolar) the drug delivery efficient of medicine greatly, its microparticle ratio can reach 60%, rather has only 35% and breathe heavily to find pleasure in.In addition, also can modify to control its release the Nano medication granule.So nanometer formulation has the incomparable advantage of present metered dose inhalation aerosol micron dosage form, therefore will become the strong competitor of inhalable formulations.
Following example only is to illustrate for example; and should not explain or be interpreted as protection scope of the present invention is done any restriction; because method of the present invention is a kind of preparation method of blanket nano-particle; so; can not carry out exhaustive examples to all medicines and biomolecule or their compositions, mixture, only enumerate some representational medicines and biological example to be illustrated more clearly in the present invention at this.
Embodiment 1
Lecithin is dissolved in isopropyl alcohol and makes surfactant solution (mass ratio is a lecithin: isopropyl alcohol=1: 3).56.3mL surfactant solution joins in the 43.5mL isobutyltrimethylmethane., vibration was evenly left standstill 30 minutes.15% (mass percent) albuterol aqueous solution that adds 23.8mL then, thermal agitation, mix homogeneously makes it to become microemulsion.
The Standard Operating Procedure of albuterol preparation of nanoparticles is as follows.Spray dryer under the duty of standard with above-mentioned microemulsion spray drying.Finish, reclaim the dry thing that is deposited in spray chamber, whirlwind centrifuge and the catcher with the normal heptane dissolving.Natural drying under the room temperature is removed normal heptane, the exsiccant particulate mixture of nanometer albuterol that contains that obtains, and the mean diameter of nano-particle is near 20nm.
Get 30mg mixture (containing medicine 7.5mg) and insert in the aerosol container, add the 1mL normal heptane Nano medication uniform particles is scattered in wherein.With the sealing of 100 μ L metering valves, inject 6.5mL propellant HFC134a then, promptly obtain the aerosol in the dispersive fluid of Nano medication uniform particles.The nano aerosol of this 100 μ g/ spray can keep highly stable dispersity.Measuring its microparticle ratio (particle diameter＜5.8 μ m) with lung model is 58%.
Embodiment 2
In embodiment 1, take by weighing 30mg (containing medicine 7.5mg) insert in the aerosol container above-mentioned spray-dried prepared containing in the particulate mixture of Nano medication, inject the 1mL pentane Nano medication uniform particles is scattered in wherein.With the sealing of 100 μ L metering valves, and then inject 6.5mL propellant HFC134a, promptly obtain the aerosol in the dispersive fluid of Nano medication uniform particles.The nano aerosol of this 100 μ g/ spray can keep highly stable dispersity.Measuring its microparticle ratio (particle diameter＜5.8 μ m) with lung model is 61%.
Embodiment 3
In embodiment 1, adopt the chromatography technology to remove the above-mentioned spray-dried prepared surfactant that contains in the particulate mixture of Nano medication, heptane is as mobile phase.Collection contains the mobile phase of drug particles, the dry nanometer albuterol granule that gets.Taking by weighing the 13mg drug particles inserts in the aerosol container, seal with 100 μ L metering valves, inject 2mL propellant normal butane earlier the Nano medication uniform particles is scattered in wherein, inject 4.5mL propellant HFC227 then, promptly obtain the aerosol in the dispersive fluid of Nano medication uniform particles.The nano aerosol of this 200 μ g/ spray can keep highly stable dispersity.Measuring its microparticle ratio (particle diameter＜5.8 μ m) with lung model is 64%.
Embodiment 4
Lecithin is dissolved in isopropyl alcohol and makes surfactant solution (mass ratio is a lecithin: isopropyl alcohol=1: 3).56.3mL surfactant solution join in the 43.5mL isobutyltrimethylmethane., vibration was evenly left standstill 30 minutes.10mg/mL (mass percent) the ipratropium bromide solution that adds 23.8mL then, thermal agitation, mix homogeneously makes it to become microemulsion.According to the Standard Operating Procedure of preparation of nanoparticles, make and contain the particulate mixture of nanometer ipratropium bromide.The mean diameter of nano-particle is near 47nm.
Adopt the chromatography technology to remove surfactant, heptane is as mobile phase.Collection contains the mobile phase of drug particles, the dry nanometer ipratropium bromide granule that gets.Get 1.5mg nanometer ipratropium bromide granule and insert in the aerosol container, add the 0.2mL normal heptane Nano medication uniform particles is scattered in wherein.With the sealing of 100 μ L metering valves, inject 7.3mL propellant HFC134a then, promptly obtain the aerosol in the dispersive fluid of Nano medication uniform particles.The nano aerosol of this 20 μ g/ spray can keep highly stable dispersity.Measuring its microparticle ratio (particle diameter＜5.8 μ m) with lung model is 62%.
Embodiment 5
In embodiment 4, above-mentioned spray-dried preparation takes by weighing 1.5mg in the isolated Nano medication granule of chromatographic technique and inserts in the aerosol container, adds the 0.2mL n-hexane Nano medication uniform particles is scattered in wherein.With the sealing of 100 μ L metering valves, inject 7.3mL propellant HFC134a then, promptly obtain the aerosol in the dispersive fluid of Nano medication uniform particles.The nano aerosol of this 20 μ g/ spray can keep highly stable dispersity.Measuring its microparticle ratio (particle diameter＜5.8 μ m) with lung model is 61%.
Embodiment 6
In embodiment 4, above-mentioned spray-dried preparation, taking by weighing 0.75mg in the isolated Nano medication granule of chromatographic technique inserts in the aerosol container, seal with 100 μ L metering valves, injecting 2mL propellant iso-butane earlier is scattered in wherein the Nano medication uniform particles, inject 5.5mL propellant HFC134a then, promptly obtain the aerosol in the dispersive fluid of Nano medication uniform particles.The nano aerosol of this 10 μ g/ spray can keep highly stable dispersity.Measuring its microparticle ratio (particle diameter＜5.8 μ m) with lung model is 69%.
Embodiment 7
In embodiment 4, above-mentioned spray-dried preparation, taking by weighing 3mg in the isolated Nano medication granule of chromatographic technique inserts in the aerosol container, seal with 100 μ L metering valves, injecting 1mL propellant propane earlier is scattered in wherein the Nano medication uniform particles, inject 5.5mL propellant HFC134a then, promptly obtain the aerosol in the dispersive fluid of Nano medication uniform particles.The nano aerosol of this 40 μ g/ spray can keep highly stable dispersity.Measuring its microparticle ratio (particle diameter＜5.8 μ m) with lung model is 68%.
Embodiment 8
Lecithin is dissolved in isopropyl alcohol and makes surfactant solution (mass ratio is a lecithin: isopropyl alcohol=1: 3).11.3mL surfactant solution joins in the 8.7mL isobutyltrimethylmethane., vibration was evenly left standstill 30 minutes.30mg/mL (mass percent) insulin solutions that adds 4.9mL then, thermal agitation, mix homogeneously makes it to become microemulsion.According to the Standard Operating Procedure of preparation of nanoparticles, make and contain the particulate mixture of nanometer insulin.The mean diameter of nano-particle is near 39nm.
Adopt chromatography to remove surfactant, normal heptane is as mobile phase.Collect the particulate mobile phase of insulin, natural drying obtains nanometer insulin granule.Get 60mg nanometer insulin granule and insert in the aerosol container, add 400 μ L normal heptane the Nano medication uniform particles is scattered in wherein.With the sealing of 100 μ L metering valves, inject 5.6mL propellant HFC134a then, promptly obtain the aerosol in the dispersive fluid of Nano medication uniform particles.The nano aerosol of this 1mg/ spray can keep highly stable dispersity.Measuring its microparticle ratio (particle diameter＜5.8 μ m) with lung model is 65%.
Embodiment 9
In embodiment 8, above-mentioned spray-dried preparation is got 120mg in the isolated nanometer insulin of the chromatographic technique granule and is inserted in the aerosol container, with the sealing of 100 μ L metering valves, injects 1.5mL propane the Nano medication uniform particles is scattered in wherein.Inject 4.5mL HFC134a then, promptly obtain the aerosol in the dispersive fluid of Nano medication uniform particles.The nano aerosol of this 2mg/ spray can keep highly stable dispersity.Measuring its microparticle ratio (particle diameter＜5.8 μ m) with lung model is 68%.
Lecithin is dissolved in isopropyl alcohol and makes surfactant solution (mass ratio is a lecithin: isopropyl alcohol=1: 3).11.3mL surfactant solution joins in the 8.7mL isobutyltrimethylmethane., vibration was evenly left standstill 30 minutes.20mg/mL (mass percent) fentanyl citrate that adds 4.8mL then, thermal agitation, mix homogeneously makes it to become microemulsion.According to the Standard Operating Procedure of preparation of nanoparticles, make and contain the particulate mixture of nanometer fentanyl citrate.The mean diameter of nano-particle is near 45nm.
Adopt chromatography to remove surfactant, heptane is as mobile phase.Collect the particulate mobile phase of fentanyl citrate, drying obtains nanometer fentanyl citrate granule.Get 6mg nanometer fentanyl citrate granule and insert in the aerosol container,, inject 1mL propellant iso-butane the Nano medication uniform particles is scattered in wherein with the sealing of 100 μ L metering valves.Inject 5mL propellant HFC134a then, promptly obtain the aerosol in the dispersive fluid of Nano medication uniform particles.The nano aerosol of this 0.1mg/ spray can keep highly stable dispersity.Measuring its microparticle ratio (particle diameter＜5.8 μ m) with lung model is 69%.
In above-mentioned all embodiment, its quickly drying method can also be supersonic jet spray drying technology, vacuum microwave quick drying technology, quick drying tunnel technology, expansion drying, other drying means or their Aassociation drying.
Isolation technics in embodiment 3-10 can also adopt absorption, ion exchange, chromatography, membrance separation, infiltration, nanofiltration, ultrafiltration, microfiltration, dialysis, separation method such as centrifugal, or their combination separation method.
It should be noted that term " propellant " among the application can adopt comprises ether, as dimethyl ether; Alkane such as propane, normal butane, iso-butane, isopentane; Fluoric ether, as Difluoroethane (HFC152a), tetrafluoroethane (HFC134a), heptafluoro-propane (HFC227); The chloro fluoric ether, as isceon (CFC11), dichlorodifluoromethane (CFC12), dichlorotetra-fluoroethane (CFC114), dichloro one fluoroethane (HCFC141b), chlorodifluoroethane (HCFC142b), or the propellant of a lot of types of their mixture propellant or the like, the selection of this propellant type is all expected to those skilled in the art easily, enumerates no longer one by one here.Term among the application " cosolvent " can adopt alkane, aromatic hydrocarbons or the cycloalkane of medium chain C5-C8, and the cosolvent type that provides in embodiment, other cosolvent type is no longer enumerated here.The preparation process of " microemulsion " among the application has been very perfect technology, the any chemicals and biomolecule that can be prepared to microemulsion can obtain its nano-particle and the aerosol that utilizes this nano-particle to make through preparation method of the present invention, clearly, preparation method of the present invention is a kind of method of generally using, chemicals and biomolecule are had no particular limits, as long as can prepare its microemulsion, can prepare its nano-particle in conjunction with rapid draing again, and make aerosol, therefore, chemicals and biomolecule are not done special restriction, this statement also can obtain the abundant support of description, here repeat no more the embodiment of various chemicalses and biomolecule, those of ordinary skills can know and know that this preparation method can obtain the aerosol of various chemicalses and biomolecule.In addition, it should be noted that, in each process of system of microemulsion, there is no particular limitation for parameters such as the weight of its various compositions, it can do the variation of certain limit as required, equally, chemicals need make corresponding changes according to different medicine or biotype according to the demand of treatment with the dispersion amount of cosolvent at propellant or propellant with the biomolecule nano-particle, here do not limit its quantity especially yet, those skilled in the art can expect, because the universality of this method, so the medicament categories of preparation is various, the consumption of contained drug also has very big-difference in its aerosol, these have all depended on the purpose of treatment and the kind of medicine, therefore, the chemicals in every spray or the amount of biomolecule are not done special qualification at this, and the example is also enumerated no longer one by one.
Although above embodiments of the invention are described in detail and illustrate, should indicatedly be, we can carry out various changes and modification to the foregoing description, but these do not break away from the scope that spirit of the present invention and appended claim are put down in writing.
Claims (26)
1. the quantitative nano aerosol of chemicals or biomolecule, this aerosol are that the nanoparticulate dispersed of the chemicals that obtains by the method that will comprise microemulsified and rapid draing step or biomolecule is in propellant or be dispersed in the mixture of cosolvent and propellant and prepared.
2. quantitative nano aerosol as claimed in claim 1, it is characterized in that described chemicals and biomolecule comprise various chemicalses, protein, polypeptide, nucleic acid or various active composition and the mixture of depositing or contain the mixture of active component.
3. quantitative nano aerosol as claimed in claim 1 is characterized in that, described nano particle diameter is less than 300nm, its mean diameter 1-90nm.
4. quantitative nano aerosol as claimed in claim 3 is characterized in that described nano particle diameter is less than 100nm.
5. quantitative nano aerosol as claimed in claim 3 is characterized in that, the mean diameter 5-50nm of described nano particle diameter.
6. as the described quantitative nano aerosol of claim 1-5, it is characterized in that described nano-particle is spherical particle and/or other particle shape.
7. as the described quantitative nano aerosol of claim 1-5, it is characterized in that described quick drying technology can be spray drying, supersonic jet spray drying, vacuum microwave rapid draing, quick drying tunnel, expansion drying, other quick drying technology or their Aassociation drying.
8. as the described quantitative nano aerosol of claim 1-5, it is characterized in that, described microemulsified can be the microemulsion technology of preparing of any routine, with the liquid of soluble chemistry medicine or biomolecule at surfactant or contain under the effect of surfactant solution of cosurfactant to be dispersed in and carry out the microemulsion preparation in another immiscible solvent with drop form less than 100nm.
9. quantitative nano aerosol as claimed in claim 8 is characterized in that, described liquid can be water or oil phase; Described immiscible solvent can be oil phase or water accordingly.
10. quantitative nano aerosol as claimed in claim 9 is characterized in that, described oil phase can be alkane, aromatic hydrocarbons, the cycloalkane of medium carbochain C5-C8.
11. quantitative nano aerosol as claimed in claim 8 is characterized in that, described surfactant comprises anion surfactant, cationic surfactant, non-ionic surface active agent, zwitterionic surfactant or their mixture.
12. quantitative nano aerosol as claimed in claim 8, it is characterized in that, described surfactant can be fatty glyceride, fatty acid cane sugar ester, fatty acid sorbitan ester, fatty acid propylene glycol ester, soybean phospholipid, Radix Acaciae senegalis, alginic acid, sodium caseinate, gelatin, egg yolk, or other surfactant types comprise contain the amino acids ester surfactant, in conjunction with polysaccharide or proteinic high molecular surfactant or granule surface activity agent.
13. quantitative nano aerosol as claimed in claim 8 is characterized in that, described cosurfactant is generally alcohol, alcohol ether or the carboxylic acid of medium carbochain C3-C8.
14., it is characterized in that described propellant is can produce enough vapour pressures and produce ether, alkane, fluorohydrocarbon, chlorohydrocarbon, chloro fluorohydrocarbon of impelling effect and composition thereof as the described quantitative nano aerosol of claim 1-5.
15. quantitative nano aerosol as claimed in claim 14 is characterized in that, described ether can be dimethyl ether; Described alkane can be propane, normal butane, iso-butane, isopentane; Described fluorohydrocarbon can be a Difluoroethane, tetrafluoroethane, heptafluoro-propane; Described chloro fluorohydrocarbon can be isceon, dichlorodifluoromethane, dichlorotetra-fluoroethane, dichloro one fluoroethane, chlorodifluoroethane.
16., it is characterized in that described propellant is insoluble for the Nano medication granule as the described quantitative nano aerosol of claim 1-5.
17., it is characterized in that described cosolvent can be alkane, aromatic hydrocarbons or the cycloalkane of medium chain C5-C8 as the described quantitative nano aerosol of claim 1-5.
18., it is characterized in that the chemicals in the every spray of described aerosol or the amount of biomolecule require to select according to its corresponding treatment as described each quantitative nano aerosol of claim 1-5.
19. quantitative nano aerosol as claimed in claim 18 is characterized in that, according to medicament categories, the chemicals that contains in every spray or the amount of biomolecule can be 0.01mg-2mg.
20. the preparation method of the quantitative nano aerosol of chemicals or biomolecule, comprise the nano-particle of the chemicals that will obtain through microemulsified and rapid draing step or biomolecule or nano-particle and surfactant mixtures be dispersed in the propellant or be dispersed in cosolvent and the mixture of propellant in step.
21. preparation method as claimed in claim 20, it is characterized in that described quick drying technology can be spray drying, supersonic jet spray drying, vacuum microwave rapid draing, quick drying tunnel, expansion drying, other quick drying technology or their Aassociation drying.
22., it is characterized in that this preparation method can also comprise a separating step after microemulsified and the rapid draing, so that the nano-particle of chemicals or biomolecule separates with surfactant as the described preparation method of claim 20-21.
23. preparation method as claimed in claim 22 is characterized in that, described separating step can adopt absorption, ion exchange, chromatography, membrance separation, infiltration, nanofiltration, ultrafiltration, microfiltration, dialysis, centrifugal separation method, or their combination separation method.
24. the preparation method of chemicals or biomolecule nano-particle, comprise microemulsified and rapid draing step, wherein microemulsified can be the microemulsion technology of preparing of any routine, and with the liquid of soluble chemistry medicine or biomolecule at surfactant or contain and be dispersed in another immiscible solvent with drop form under the effect of surfactant solution of cosurfactant and carry out the microemulsion preparation less than 100 nanometers, prepare nano-particle through the rapid draing step then.
25. preparation method as claimed in claim 24, it is characterized in that described quick drying technology can be spray drying, supersonic jet spray drying, vacuum microwave rapid draing, quick drying tunnel, expansion drying or other quick drying technology or their combination drying technology.
26. the purposes of the chemicals of a claim 1-19 or the quantitative nano aerosol of biomolecule, it transmits the application of medicine as lung transmission, mouth or nose.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2006100993768A CN101108166B (en) | 2006-07-19 | 2006-07-19 | Quantitative nano aerosol and method of manufacturing the same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2006100993768A CN101108166B (en) | 2006-07-19 | 2006-07-19 | Quantitative nano aerosol and method of manufacturing the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101108166A true CN101108166A (en) | 2008-01-23 |
| CN101108166B CN101108166B (en) | 2011-07-27 |
Family
ID=39040556
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2006100993768A Expired - Fee Related CN101108166B (en) | 2006-07-19 | 2006-07-19 | Quantitative nano aerosol and method of manufacturing the same |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101108166B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104415016A (en) * | 2013-08-22 | 2015-03-18 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | Application of dry curcumin nano-powder inhalant in treatment of acute lung injury |
| CN108186398A (en) * | 2018-02-09 | 2018-06-22 | 中山市天图精细化工有限公司 | A kind of refrigerant aerosol of cooling composition and aerosol products |
| CN111034716A (en) * | 2018-10-11 | 2020-04-21 | 江苏功成生物科技有限公司 | Normal-temperature volatile type insecticidal spray composition and application thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7459146B2 (en) * | 2003-05-30 | 2008-12-02 | 3M Innovative Properties Company | Stabilized aerosol dispersions |
-
2006
- 2006-07-19 CN CN2006100993768A patent/CN101108166B/en not_active Expired - Fee Related
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104415016A (en) * | 2013-08-22 | 2015-03-18 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | Application of dry curcumin nano-powder inhalant in treatment of acute lung injury |
| CN108186398A (en) * | 2018-02-09 | 2018-06-22 | 中山市天图精细化工有限公司 | A kind of refrigerant aerosol of cooling composition and aerosol products |
| CN111034716A (en) * | 2018-10-11 | 2020-04-21 | 江苏功成生物科技有限公司 | Normal-temperature volatile type insecticidal spray composition and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101108166B (en) | 2011-07-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4752425A (en) | High-encapsulation liposome processing method | |
| EP0833614B1 (en) | System and method for producing drug-loaded microparticles | |
| TW550089B (en) | Dispersible macromolecule compositions and methods for their preparation and use | |
| ES2895376T3 (en) | Method and apparatus for producing dry particles | |
| EP1274403B1 (en) | Particulate composition | |
| ES2267268T3 (en) | INCORPORATION OF ACTIVE SUBSTANCES IN VEHICLE MATRICES. | |
| CN1798549B (en) | Stabilized aerosol dispersions | |
| US20030035775A1 (en) | Nonaqueous solutions and suspensions of macromolecules for pulmonary delivery | |
| JP5021149B2 (en) | Medical aerosol formulation | |
| KR20050042052A (en) | Spray drying methods and compositions thereof | |
| Jawahar et al. | Nanoparticles: A novel pulmonary drug delivery system for tuberculosis | |
| JP7236485B2 (en) | Method for producing composite particles for inhalation using three-fluid nozzle | |
| CN101108166B (en) | Quantitative nano aerosol and method of manufacturing the same | |
| JPH01501228A (en) | High concentration liposome treatment method | |
| Li et al. | Innovative pMDI formulations of spray-dried nanoparticles for efficient pulmonary drug delivery | |
| US8207236B2 (en) | Method for the production of porous particles | |
| CN107412783A (en) | A kind of preparation method for being enclosed with the protein particulate for being insoluble in water medicine | |
| Li et al. | Preparation of nanoparticles by spray-drying and their use for efficient pulmonary drug delivery | |
| KR20010053299A (en) | Particulate delivery systems and methods of use | |
| CN101380309B (en) | Quantitative inhalation aerosol and preparation method thereof | |
| JP2004513974A5 (en) | ||
| JP2004513974A (en) | Synthesis of fine particles | |
| WO2003015756A1 (en) | Preparation of microparticles | |
| Cheow et al. | Preparations of dry-powder therapeutic nanoparticle aerosols for inhaled drug delivery | |
| CN118234484A (en) | Microfluidic preparation of fluorocarbon crosslinked vesicles |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: LI HAOYING Free format text: FORMER OWNER: LU MINGHUA Effective date: 20111103 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 710061 XI'AN, SHAANXI PROVINCE TO: 215021 SUZHOU, JIANGSU PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20111103 Address after: Xinghu Street Industrial Park in Suzhou city of Jiangsu Province, No. 833 4-1-804 215021 Patentee after: Li Haoying Address before: 710061 Shaanxi city of Xi'an province Xiaozhaizigou West Orient Hotel Room 518 Patentee before: Lu Minghua |
|
| ASS | Succession or assignment of patent right |
Owner name: NANTONG RUIKANGDA BIOTECHNOLOGY CO., LTD. Free format text: FORMER OWNER: LI HAOYING Effective date: 20121218 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 215021 SUZHOU, JIANGSU PROVINCE TO: 226010 NANTONG, JIANGSU PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20121218 Address after: 226010 Jiangsu city of Nantong province Nantong michimori Development Zone, Road No. 188, block C 908 Patentee after: NANTONG RUIKANGDA BIOTECHNOLOGY CO., LTD. Address before: Xinghu Street Industrial Park in Suzhou city of Jiangsu Province, No. 833 4-1-804 215021 Patentee before: Li Haoying |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20110727 Termination date: 20170719 |